13,655 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Purchased by Algert Global LLC

Algert Global LLC purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 13,655 shares of the specialty pharmaceutical company's stock, valued at approximately $1,682,000.

Several other hedge funds have also made changes to their positions in the company. LSV Asset Management lifted its holdings in Jazz Pharmaceuticals by 1.5% during the 4th quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock worth $311,699,000 after buying an additional 37,108 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after buying an additional 115,102 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Jazz Pharmaceuticals by 18.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after buying an additional 320,724 shares in the last quarter. Capital World Investors lifted its holdings in Jazz Pharmaceuticals by 5.7% during the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock worth $236,860,000 after buying an additional 104,195 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after buying an additional 315,608 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on JAZZ. Piper Sandler reissued an "overweight" rating and set a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. HC Wainwright boosted their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Needham & Company LLC restated a "buy" rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Royal Bank of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Robert W. Baird reduced their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $182.79.

Jazz Pharmaceuticals Stock Up 5.9%

NASDAQ:JAZZ traded up $5.80 during midday trading on Monday, hitting $103.58. 1,659,789 shares of the company were exchanged, compared to its average volume of 836,767. The company has a fifty day simple moving average of $118.96 and a 200 day simple moving average of $122.29. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $6.38 billion, a PE ratio of 14.59, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. Jazz Pharmaceuticals's revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.68 earnings per share. As a group, equities analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the transaction, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This represents a 36.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,236 shares of company stock worth $3,956,190. 4.20% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.